Physician profile
Alvaro E Castillo
NPI 1891939385
$2,841.41
in general payments reported to CMS, 2019-2025
14 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $36.27 · 2021: $154 · 2022: $36.62 · 2023: $225 · 2024: $481 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $683.74 | 2019 | |
| Cook Medical LLC | $515.07 | 2019 | |
| Acera Surgical, INC. | $490.11 | 2023-2025 | Restrata Wound Matrix |
| Ethicon US, LLC | $374.68 | 2019-2022 | |
| Tela Bio, INC. | $193.41 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Innovation Technologies INC | $188.15 | 2024 | Irrisept |
| Stryker Corporation | $144.97 | 2019 | |
| Asensus Surgical, INC. | $126.75 | 2019 | |
| Boston Scientific Corporation | $36.27 | 2020 | |
| Avanos Medical | $29.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.74 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.70 | 2023 | Quviviq |
| Acell, INC. | $12.71 | 2019 | |
| Coopersurgical, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvaro Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.